Infinity is playing catch-up to two otherbiotechfirms, Conforma Therapeutics and Kosan Biosciences, in the race to develop the first heat-shock blockers.
At the end of this month, they will announce a new research consortium with a number of other multinational agri-biotech firms, to pin down apomixis through the sharing of high-tech genomic tools and databases.
Then they invariably overlook the strengths of also-ran firms, which field large sales forces and often buy or strike alliances with biotech and other drug outfits that lack marketing muscle but create potential breakthrough products.